Aclaris Therapeutics
ACRS
Aclaris Therapeutics (ACRS) news
Recent news
Aclaris Therapeutics, Inc.: Canaccord Genuity initiates coverage with buy rating; target price $10
AInvest Wire · Sep 1, 2026Aclaris Therapeutics, Inc.: expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in Q4 of 2026
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced plans to initiate a phased multi-part Phase 2b trial of modzatinib in lichen planus (LP) in the fourth quarter of 2026. This decision follows recent clinical and corporate updates that highlight the company’s strategic focus on advancing its…
AInvest Wire · Aug 6, 2026Aclaris Therapeutics, Inc. files for mixed shelf; size not disclosed - SEC filing
AInvest Wire · Aug 6, 2026Aclaris Therapeutics expects cash to fund operations through end of 2028
AInvest Wire · Aug 6, 2026Aclaris 2Q revenue $1.6M, estimate $1.56M
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.